Literature DB >> 32271569

Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A3 Adenosine Receptors: Affinity Enhancement by N6-(2-Phenylethyl) Substitution.

Dilip K Tosh, Veronica Salmaso, Harsha Rao, Amelia Bitant1, Courtney L Fisher1, David I Lieberman, Helmut Vorbrüggen2, Marc L Reitman, Oksana Gavrilova, Zhan-Guo Gao, John A Auchampach1, Kenneth A Jacobson.   

Abstract

Dopamine-derived N6-substituents, compared to N6-(2-phenylethyl), in truncated (N)-methanocarba (bicyclo[3.1.0]hexyl) adenosines favored high A3 adenosine receptor (AR) affinity/selectivity, e.g., C2-phenylethynyl analogue 15 (MRS7591, Ki = 10.9/17.8 nM, at human/mouse A3AR). 15 was a partial agonist in vitro (hA3AR, cAMP inhibition, 31% Emax; mA3AR, [35S]GTP-γ-S binding, 16% Emax) and in vivo and also antagonized hA3AR in vitro. Distal H-bonding substitutions of the N6-(2-phenylethyl) moiety particularly enhanced mA3AR affinity by polar interactions with the extracellular loops, predicted using docking and molecular dynamics simulation with newly constructed mA3AR and hA3AR homology models. These hybrid models were based on an inactive antagonist-bound hA1AR structure for the upper part of TM2 and an agonist-bound hA2AAR structure for the remaining TM portions. These species-independent A3AR-selective nucleosides are low efficacy partial agonists and novel, nuanced modulators of the A3AR, a drug target of growing interest.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32271569      PMCID: PMC7443318          DOI: 10.1021/acs.jmedchem.0c00235

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  59 in total

1.  Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor.

Authors:  Zhan-Guo Gao; Aishe Chen; Dov Barak; Soo-Kyung Kim; Christa E Müller; Kenneth A Jacobson
Journal:  J Biol Chem       Date:  2002-03-12       Impact factor: 5.157

2.  Scalable molecular dynamics with NAMD.

Authors:  James C Phillips; Rosemary Braun; Wei Wang; James Gumbart; Emad Tajkhorshid; Elizabeth Villa; Christophe Chipot; Robert D Skeel; Laxmikant Kalé; Klaus Schulten
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

3.  Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity.

Authors:  Robert K Y Cheng; Elena Segala; Nathan Robertson; Francesca Deflorian; Andrew S Doré; James C Errey; Cédric Fiez-Vandal; Fiona H Marshall; Robert M Cooke
Journal:  Structure       Date:  2017-07-14       Impact factor: 5.006

Review 4.  Unifying family A GPCR theories of activation.

Authors:  Benjamin G Tehan; Andrea Bortolato; Frank E Blaney; Malcolm P Weir; Jonathan S Mason
Journal:  Pharmacol Ther       Date:  2014-02-19       Impact factor: 12.310

5.  Species differences and mechanism of action of A3 adenosine receptor allosteric modulators.

Authors:  Lili Du; Zhan-Guo Gao; Silvia Paoletta; Tina C Wan; Elizabeth T Gizewski; Samantha Barbour; Jacobus P D van Veldhoven; Adriaan P IJzerman; Kenneth A Jacobson; John A Auchampach
Journal:  Purinergic Signal       Date:  2017-11-23       Impact factor: 3.765

Review 6.  The A3 adenosine receptor: history and perspectives.

Authors:  Pier Andrea Borea; Katia Varani; Fabrizio Vincenzi; Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Stefania Merighi; Stefania Gessi
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Molecular basis for high-affinity agonist binding in GPCRs.

Authors:  Tony Warne; Patricia C Edwards; Andrew S Doré; Andrew G W Leslie; Christopher G Tate
Journal:  Science       Date:  2019-05-09       Impact factor: 47.728

8.  Knockout of A3 adenosine receptors reduces mouse intraocular pressure.

Authors:  Marcel Y Avila; Richard A Stone; Mortimer M Civan
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-09       Impact factor: 4.799

9.  Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists.

Authors:  Seiji Miwatashi; Yasuyoshi Arikawa; Tatsumi Matsumoto; Keiko Uga; Naoyuki Kanzaki; Yumi N Imai; Shigenori Ohkawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  2008-08       Impact factor: 1.645

10.  Peripheral Adenosine A3 Receptor Activation Causes Regulated Hypothermia in Mice That Is Dependent on Central Histamine H1 Receptors.

Authors:  Jesse Lea Carlin; Dilip K Tosh; Cuiying Xiao; Ramón A Piñol; Zhoumou Chen; Daniela Salvemini; Oksana Gavrilova; Kenneth A Jacobson; Marc L Reitman
Journal:  J Pharmacol Exp Ther       Date:  2015-11-25       Impact factor: 4.030

View more
  7 in total

1.  A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity.

Authors:  Dilip K Tosh; Veronica Salmaso; Ryan G Campbell; Harsha Rao; Amelia Bitant; Eline Pottie; Christophe P Stove; Naili Liu; Oksana Gavrilova; Zhan-Guo Gao; John A Auchampach; Kenneth A Jacobson
Journal:  Eur J Med Chem       Date:  2021-11-19       Impact factor: 6.514

2.  Pharmacological characterization of DPTN and other selective A3 adenosine receptor antagonists.

Authors:  Zhan-Guo Gao; R Rama Suresh; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2021-10-28       Impact factor: 3.765

3.  Selective A3 Adenosine Receptor Antagonist Radioligand for Human and Rodent Species.

Authors:  R Rama Suresh; Zhan-Guo Gao; Veronica Salmaso; Eric Chen; Ryan G Campbell; Russell B Poe; Theodore E Liston; Kenneth A Jacobson
Journal:  ACS Med Chem Lett       Date:  2022-03-02       Impact factor: 4.632

Review 4.  Purinergic GPCR transmembrane residues involved in ligand recognition and dimerization.

Authors:  Veronica Salmaso; Shanu Jain; Kenneth A Jacobson
Journal:  Methods Cell Biol       Date:  2021-07-12       Impact factor: 1.829

Review 5.  Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  ChemMedChem       Date:  2020-09-18       Impact factor: 3.540

Review 6.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

Review 7.  In Silico Drug Design for Purinergic GPCRs: Overview on Molecular Dynamics Applied to Adenosine and P2Y Receptors.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  Biomolecules       Date:  2020-05-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.